Works matching IS 13524585 AND DT 2012 AND VI 18 AND IP 3


Results: 18
    1
    2
    4
    5
    6
    7

    Immunological and clinical consequences of treating a patient with natalizumab.

    Published in:
    Multiple Sclerosis Journal, 2012, v. 18, n. 3, p. 335, doi. 10.1177/1352458511421919
    By:
    • Schwab, Nicholas;
    • Höhn, Karin G;
    • Schneider-Hohendorf, Tilman;
    • Metz, Imke;
    • Stenner, Max-Philipp;
    • Jilek, Samantha;
    • Du Pasquier, Renaud A;
    • Gold, Ralf;
    • Meuth, Sven G;
    • Ransohoff, Richard M;
    • Brück, Wolfgang;
    • Wiendl, Heinz
    Publication type:
    Article
    8
    9
    10

    Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study.

    Published in:
    Multiple Sclerosis Journal, 2012, v. 18, n. 3, p. 314, doi. 10.1177/1352458511421054
    By:
    • Kappos, Ludwig;
    • Gold, Ralf;
    • Miller, David H;
    • MacManus, David G;
    • Havrdova, Eva;
    • Limmroth, Volker;
    • Polman, Chris H;
    • Schmierer, Klaus;
    • Yousry, Tarek A;
    • Eraksoy, Mefkure;
    • Meluzinova, Eva;
    • Dufek, Michal;
    • Yang, Minhua;
    • Dawson, Kate;
    • O’Neill, Gilmore N
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18